Asset Details
Do you wish to reserve the book?
Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial)
Do you wish to request the book?
Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial)
2024
Overview
Purpose
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the major side effects and main reasons for affecting quality of life and dose reduction or even discontinuation of treatment in breast cancer patients. One of the most widely prescribed chemotherapies is the “taxanes.” Considering that duloxetine has been used in treating neuropathies in recent years, this study aimed to investigate its effectiveness in preventing taxane-related neuropathy.
Material and methods
This is a randomized controlled trial on 47 patients: 24 received a placebo and 23 received duloxetine at 30 mg daily in the first week following the injection of paclitaxel and 60 mg during the second week in each chemotherapy cycle. Patients objective (nerve conduction velocity (NCV) values) and subjective symptoms (visual analog scale including; neuropathy, paresthesia, pain, cold sensitivity, and numbness), the grades of the patients’ neuropathy (calculated according to Common Terminology Criteria for Adverse Events (CTCAE) v.5), and the presence of complications, before and after each chemotherapy cycle, were recorded.
Results
The placebo group experienced significantly higher occurrences of new neuropathy (8/23 in duloxetine vs 16/24 in placebo,
P
= 0.029) in NCV by tibial nerve latency (− 0.28% vs 19.87%,
P
= 0.006), tibial amplitude (4.40% vs − 10.88%,
P
= 0.049), and median nerve latency (8.72% vs 31.16%,
P
= 0.039); administration of duloxetine significantly reduced the scores of neuropathies (
P
< 0.001), pain (
P
= 0.027), during chemotherapy, and 6 weeks later; however, no significant effect was observed on paresthesia, numbness, cold sensitivity, and other NCV measurements.
Conclusions
Paclitaxel can cause neuropathy, lasting for a long time. Our study showed duloxetine is potentially an effective medication that can prevent subjective and objective neuropathy.
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
/ Aged
/ Antineoplastic Agents, Phytogenic - administration & dosage
/ Antineoplastic Agents, Phytogenic - adverse effects
/ Breast Neoplasms - drug therapy
/ Cancer
/ Drugs
/ Duloxetine Hydrochloride - administration & dosage
/ Duloxetine Hydrochloride - therapeutic use
/ Female
/ Humans
/ Latency
/ Medicine
/ Nursing
/ Oncology
/ Paclitaxel - administration & dosage
/ Paclitaxel - adverse effects
/ Pain
/ Patients
/ Peripheral Nervous System Diseases - chemically induced
